| 000 | 02752 a2200733 4500 | ||
|---|---|---|---|
| 005 | 20250514050558.0 | ||
| 264 | 0 | _c20030128 | |
| 008 | 200301s 0 0 eng d | ||
| 022 | _a0006-4971 | ||
| 024 | 7 |
_a10.1182/blood-2001-11-0107 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRobinson, Stephen P | |
| 245 | 0 | 0 |
_aChemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. _h[electronic resource] |
| 260 |
_bBlood _cDec 2002 |
||
| 300 |
_a4310-6 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAlemtuzumab |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntibodies, Neoplasm _xadministration & dosage |
| 650 | 0 | 4 | _aAntilymphocyte Serum |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 | _aBone Marrow Transplantation |
| 650 | 0 | 4 |
_aCarmustine _xadministration & dosage |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aCytarabine _xadministration & dosage |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aEurope _xepidemiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aGraft Survival |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xepidemiology |
| 650 | 0 | 4 |
_aHodgkin Disease _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aLife Tables |
| 650 | 0 | 4 |
_aLymphoma, Non-Hodgkin _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelphalan _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeripheral Blood Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 |
_aPodophyllotoxin _xadministration & dosage |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aSalvage Therapy |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTransplantation Chimera |
| 650 | 0 | 4 | _aTransplantation Conditioning |
| 650 | 0 | 4 |
_aTransplantation, Homologous _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVidarabine _xadministration & dosage |
| 700 | 1 | _aGoldstone, Anthony H | |
| 700 | 1 | _aMackinnon, Stephen | |
| 700 | 1 | _aCarella, Angelo | |
| 700 | 1 | _aRussell, Nigel | |
| 700 | 1 | _ade Elvira, Carmen Ruiz | |
| 700 | 1 | _aTaghipour, Goli | |
| 700 | 1 | _aSchmitz, Norbert | |
| 773 | 0 |
_tBlood _gvol. 100 _gno. 13 _gp. 4310-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1182/blood-2001-11-0107 _zAvailable from publisher's website |
| 999 |
_c12202537 _d12202537 |
||